By Connor Hart
GoodRx Holdings will offer employers access to Eli Lilly's Zepbound through a new program designed to help companies manage the cost of weight-loss drugs.
The prescription-drug provider said Friday that employers participating in its "Employer Direct" platform will be able to provide workers with the Zepbound KwikPen at a set price of $449 per month across all doses. Employers can choose to further subsidize part of that cost.
The offering underscores GoodRx's ability to connect manufacturer pricing and employer contributions under a single infrastructure, said Laura Jensen, chief commercial officer and president of pharma direct.
GoodRx's Employer Direct platform enables employers to support access to Zepbound KwikPen without altering their core health benefit structure, the company said. The program is designed to complement--but not replace--traditional health plans, it added.
Demand for GLP-1 drugs has surged in recent years, prompting employers and insurers to seek lower-cost options as many health plans have limited or excluded coverage for the treatments.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
03-06-26 0950ET
